Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform

阿玛罗斯完成A轮融资，扩大顾问委员会以加速EvidenceEngine™眼科AI平台的市场进入

ATHERTON, Calif., June 17, 2025-- Amaros Inc. (www.amaros.ai), a leader in ophthalmic intelligence and the developer of AI-powered EvidenceEngine platform, today announced the successful close of its Series A financing. Backed by a select group of new and existing mission-aligned investors, the round validates Amaros' mission to transform fragmented clinical data into real-time, actionable intelligence for eye care..

加利福尼亚州阿瑟顿，2025年6月17日——眼科智能领域的领导者、开发AI驱动的EvidenceEngine平台的Amaros公司（www.amaros.ai）今日宣布成功完成其A轮融资。此轮融资得到了一批新的和现有的使命一致的投资者的支持，验证了Amaros将碎片化的临床数据转化为眼科护理实时、可操作情报的使命。

“This funding confirms our core belief that ophthalmology’s most underutilized asset is its own data,” said Vartan Ghazarossian, Ph.D., co-founder and CEO of Amaros. “Too much critical information remains siloed — limiting how we study, diagnose and treat eye diseases. With our AI-powered EvidenceEngine, we’re building the industry’s first dynamic real-world intelligence platform, empowering physicians, researchers and companies to transform unstructured data into life-changing insights.”.

“这笔资金证实了我们的核心信念，即眼科最未充分利用的资产是其自身的数据，”Amaros的联合创始人兼首席执行官瓦尔坦·加扎罗西安博士说。“太多关键信息仍然孤立存在，限制了我们研究、诊断和治疗眼病的方式。通过我们的人工智能驱动的EvidenceEngine，我们正在构建业界首个动态的真实世界智能平台，赋予医生、研究人员和公司将以非结构化数据转化为改变生命的洞察力的能力。”

The Series A funding will fuel continued product development, the expansion of commercial partnerships and the global scaling of Amaros’ engineering, clinical and data science teams—as the company accelerates its commercialization.

A轮融资将推动产品持续开发、商业合作伙伴关系的扩展，以及Amaros的工程、临床和数据科学团队的全球扩展——因为公司正在加速其商业化进程。

Amaros also announced the formation of a distinguished advisory board, comprised of global leaders in posterior and anterior segment eye care, artificial intelligence and clinical trial design. This elite group will play a critical role in guiding the commercialization of the EvidenceEngine and shaping its application across the full spectrum of ophthalmic innovation..

阿玛罗斯还宣布成立一个由后段和前段眼科护理、人工智能及临床试验设计领域的全球领袖组成的杰出顾问委员会。这个精英团队将在指导EvidenceEngine的商业化进程以及塑造其在眼科创新全领域中的应用方面发挥关键作用。

• David S. Boyer, M.D., is a renowned retinal specialist and senior partner at Retina-Vitreous Associates Medical Group in Los Angeles, California and lead investigator for age-related macular degeneration and diabetic retinopathy trials. He also is an adjunct clinical professor of ophthalmology at USC/Keck School of Medicine..

• 大卫·S·博耶医学博士是加利福尼亚州洛杉矶Retina-Vitreous Associates医疗集团的著名视网膜专家和资深合伙人，同时也是与年龄相关黄斑变性和糖尿病视网膜病变试验的首席研究员。他还担任南加州大学凯克医学院眼科临床兼职教授。

• David Eichenbaum, M.D., is a partner and director of research at Retina Vitreous Associates of Florida with extensive experience in retina-focused pharmaceutical development and clinical trial execution.

大卫·艾森鲍姆医学博士是佛罗里达视网膜玻璃体协会的合伙人兼研究主任，在视网膜相关的药物开发和临床试验执行方面拥有丰富的经验。

• Peter K. Kaiser, M.D., is the Chaney Family Endowed Chair in Ophthalmology Research, Cole Eye Institute, Cleveland Clinic and professor of ophthalmology, Case Western Reserve School of Medicine, and internationally recognized for excellence in retinal imaging and clinical trial design.

彼得·K·凯泽医学博士是克利夫兰诊所科尔眼科研究所的眼科研究查尼家族捐赠主席，凯斯西储大学医学院的眼科学教授，并在视网膜成像和临床试验设计方面享有国际声誉。

• T. Y. Alvin Liu, M.D., is an endowed professor in AI at the Wilmer Eye Institute, Johns Hopkins University (JHU). He is also the inaugural director of the James P. Gills Jr., M.D., and Heather Gills Artificial Intelligence Innovation Center, which is the first dedicated, endowed AI center at the JHU School of Medicine..

刘阿尔文博士（T. Y. Alvin Liu）是约翰霍普金斯大学（JHU）威尔默眼科研究所的人工智能捐赠教授。他还是詹姆斯·P·吉尔斯二世医学博士及希瑟·吉尔斯人工智能创新中心的首任主任，该中心是JHU医学院首个专注于人工智能的捐赠中心。

• Sumit P. Shah, M.D., is a partner at NJ Retina, Prism Vision Group and is clinical associate professor at Rutgers Robert Wood Johnson Medical School with extensive experience as an investigator for numerous retina-focused clinical trials.

苏米特·P·沙阿（Sumit P. Shah）医学博士是新泽西视网膜中心（NJ Retina）和棱镜视觉集团（Prism Vision Group）的合伙人，同时担任罗格斯大学罗伯特·伍德·约翰逊医学院的临床副教授，他在众多视网膜相关的临床试验中拥有丰富的研究经验。

• Michael A. Singer, M.D., is clinical professor at UT Health Science Center and director of clinical research at Medical Center Ophthalmology Associates in San Antonio, Texas and a key opinion leader in real-world data and imaging biomarkers.

• 迈克尔·A. 辛格（Michael A. Singer）博士是德克萨斯州圣安东尼奥市UT健康科学中心的临床教授，同时也是医学中心眼科协会临床研究主任，是真实世界数据和影像生物标志物领域的关键意见领袖。

• Vance Thompson, M.D., is founder of Vance Thompson Vision and a pioneer in refractive and cataract surgery, widely known for anterior-segment innovation and clinical trial leadership.

• 万斯·汤普森（Vance Thompson），医学博士，是Vance Thompson Vision的创始人，也是屈光和白内障手术领域的先驱，以眼前节创新和临床试验领导力而广为人知。

'Our advisory board brings together visionary leaders with deep expertise in clinical excellence, real-world evidence and business innovation,' said Ben Toker, co-founder and president of Amaros. 'Their insights will be pivotal as we transform fragmented and siloed data into precision intelligence —advancing clinical research, enhancing care delivery, and driving smarter commercialization.

“我们的顾问委员会汇集了在临床卓越、真实世界证据和商业创新方面具有深厚专业知识的有远见的领导者，”Amaros联合创始人兼总裁Ben Toker表示，“他们的见解将在我们将碎片化和孤立的数据转化为精准情报的过程中发挥关键作用——推动临床研究，改善医疗交付，并促进更明智的商业化。”

With their partnership, we are accelerating the adoption of ophthalmic AI and building the unified ecosystem that modern eye care demands.”.

通过他们的合作，我们正在加速眼科人工智能的采用，并构建现代眼科护理所需的统一生态系统。”

About Amaros

关于阿玛罗斯

Founded in 2019 in Silicon Valley, Amaros Inc. (www.amaros.ai) is redefining the future of ophthalmic care through deep tech innovation. Its flagship platform, EvidenceEngine, integrates diverse datasets — including electronic medical records, imaging, genomics, provider notes and claims — into structured information that provides real-time insights.

2019年成立于硅谷的Amaros公司（www.amaros.ai）正通过深度技术创新重新定义眼科护理的未来。其旗舰平台EvidenceEngine整合了多种数据集——包括电子医疗记录、影像、基因组学、医生笔记和索赔信息——将其转化为提供实时洞察的结构化信息。

Designed with a human-centric mindset, the platform empowers stakeholders across the eye care continuum to make smarter decisions, faster. From accelerating clinical trials to identifying unmet needs and optimizing treatment strategies, Amaros delivers the intelligence that modern ophthalmology demands..

该平台以以人为本的理念设计，赋能眼科护理全流程中的利益相关者更快地做出明智决策。从加速临床试验，到识别未满足的需求并优化治疗策略，Amaros 提供了现代眼科所需的智能支持。

Contact:

联系：

Media Inquiries

媒体询问

media@launchlabpartners.com

媒体@发射实验室合作伙伴.com